1,807 Shares in Johnson & Johnson $JNJ Purchased by Orgel Wealth Management LLC

Key Points

• Orgel Wealth Management LLC has purchased 1,807 shares of Johnson & Johnson, valued at approximately $276,000, marking a new investment in the healthcare giant.
• Multiple institutional investors have also increased their stakes, with Vanguard Group raising its position by 0.5%, now owning 233,962,679 shares valued at $38.8 billion.
• Johnson & Johnson reported $2.77 EPS for the last quarter, surpassing estimates, and has set its FY 2025 EPS guidance between 10.800-10.900.

Orgel Wealth Management LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,807 shares of the company's stock, valued at approximately $276,000.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Elios Financial Group Inc. grew its stake in Johnson & Johnson by 1.5% in the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC lifted its holdings in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after acquiring an additional 67 shares during the last quarter. MBA Advisors LLC lifted its stake in Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after purchasing an additional 68 shares in the last quarter. Sovereign Financial Group Inc. increased its holdings in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc grew its holdings in shares of Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. The Goldman Sachs Group raised their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a research report on Friday. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. Finally, Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $181.40.

Johnson & Johnson Trading Up 1.5%

Shares of JNJ stock traded up $2.56 on Tuesday, hitting $176.77. The stock had a trading volume of 1,645,416 shares, compared to its average volume of 8,906,436. The company's 50 day moving average price is $173.14 and its 200-day moving average price is $161.69. The firm has a market capitalization of $425.72 billion, a P/E ratio of 18.88, a P/E/G ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the business posted $2.82 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.